The Pristine Post-Market Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 142 participants.

Also called NCT05228132

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 142 participants (enrolled count) (from the registry)
Sponsor
  • C. R. Bard Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05228132
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT05228132. Allocation not applicable; no masking; primary purpose treatment. Start 2022-05-16 (actual); primary completion 2022-09-21 (actual). Results posted on 2024-04-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Pristine Post-Market Study
Condition
Kidney Failure, Chronic
Condition
Hemodialysis Complication
Condition
Hemodialysis Catheter Infection
Condition
Hemodialysis Access Failure
Condition
Central Venous Catheter Related Bloodstream Infection
Condition
End Stage Renal Disease
Intervention (Device)
Pristine™ Long-Term Hemodialysis Catheter
Lead sponsor
C. R. Bard (class: industry)

Record details

Record id
cardio:ct-nct05228132
Content hash
9267f12b92de6cd866deecd4a1e1ee618aa3aba90ad97b7b8411e053c94040fc